(+)-JQ1

Catalog No.S7110

(+)-JQ1 Chemical Structure

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

Size Price Stock Quantity  
USD 270 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

7 Customer Reviews

  • The BET protein inhibitor JQ1 reduces c-Myc expression and attenuates primary MCC cell proliferation. A, decreased c-Myc expression in MCC-3 and MCC-5 treated with JQ1 (800 nmol/L) for 72 hours by qRT-PCR and immunoblotting. The mRNA expression of target genes was normalized to that of MRPS2 and a value of 1.0 was assigned to the mRNA expression of target genes in the control group (means+SEM; **, P < 0.01 vs. control); b-actin was used as a loading control for immunoblotting.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

    Immunohistochemical staining of xenograft tumor tissues. Immunohistochemical staining of xenograft tumor tissues with the indicated antibodies. p21-, p27-, p57-, and Ki67 positive cells (brown staining) were quantified at x400 magnification (meansSEM;**, P < 0.01;***, P < 0.001 vs. control); scale bars, 10 um.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

  • (D) Effect of JQ1 on alterations of actin cytoskeleton in VEGF-induced HUVECs. The cells were pretreated with DMSO or JQ1 (100 nM) for 6 h, and stimulated with VEGF (10 ng/mL) for 12 h. F-actin (red) and nuclei (blue) were stained with phalloidin and DAPI, respectively. Representative images from 3 independent experiments.

    Sci Rep, 2016, 6:23770.. (+)-JQ1 purchased from Selleck.

    Sensitivity of BEZ235-resistant cells to JQ-1 using the MTT assay.

    Oncotarget, 2016, 6(7):5134-46.. (+)-JQ1 purchased from Selleck.

  • B. Repressed MCC-3 xenograft tumor growth upon combined treatment with MLN0128 and JQ1. Tumor bearing mice were treated with MLN0128 or vehicle at 1 mg/kg/day by oral gavage and JQ1 or vehicle at 50 mg/kg/day by i.p. injection for a period of 30 days. C. A more effective reduction of MCC-3 xenograft tumor growth in the group treated with combined therapy. Fold-reduction of tumor growth was calculated as average tumor growth of control group divided by average tumor growth of treatment group. Tumor growth was calculated as final average tumor volume minus initial average tumor volume in each group.

    Oncotarget, 2016, 7(6):6576-92.. (+)-JQ1 purchased from Selleck.

    JQ1 induces cell cycle arrest and apoptosis in Cal27 cells. (C) Cal27 cells were treated with JQ1 for 24 h and whole cell lysates were tested by western blot assays for the expression of cleaved-caspase-3. GAPDH was used as a loading control. (D) Apoptosis of Cal27 cells treated with JQ1 at 0 and 0.5 µM JQ1; *P<0.05 vs. control (the DMSO group)

    Oncol Rep, 2016, 36(4):1989-96.. (+)-JQ1 purchased from Selleck.

  • Effect of BET domain family inhibition on AMI damage in cardiomyocytes. (A) LDH and (B) CK-MB activity in the serum. #P<0.01 vs. sham group; @P<0.05 and &P<0.01 vs. AMI group. BET, bromodomain and extra-terminal; AMI, acute myocardial infarction; LDH, lactate dehydrogenase; CK-MB, creatine kinase MB isoenzyme.

    Exp Ther Med, 2015, 10(6):2319-2324.. (+)-JQ1 purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.
Features (+)-JQ1 is more effective than (-)-JQ1.
Targets
BRD4 (2) [1]
(Cell-free assay)
BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. [1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. [2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. [3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  NFG2UWJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NY\zbI5uOjVyL{WwNE8yODByIH7N M36wblI1NzR6L{eyJIg> NHHDRWJFVVOR MVLpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy M3OxUFI3PzB5OEix
BCPAP M3np[WNmdGxiVnnhZoltcXS7IFHzd4F6 NFXpUXUzPTBxNUCwM|ExODBibl2= Ml:0NlQwPDhxN{KgbC=> Ml\oSG1UVw>? Mkf4bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> NVXR[IdnOjZ5MEe4PFE>
K1  NXzBUVFzS2WubDDDfYNt\SCDc4PhfS=> MWSyOVAwPTByL{GwNFAhdk1? M363c|czKGh? M2LGcWROW09? NYrKcFg4[XK{ZYP0d{Bk\WyuIHP5Z4xmKGG2IFewM2cyKHCqYYPl NILkVZkzPjdyN{i4NS=>
BCPAP NF[ySoVE\WyuIFP5Z4xmKEG|c3H5 MlG0NlUxNzVyMD:xNFAxKG6P M1n6XlczKGh? M4PnVGROW09? MVfhdpJme3S|IHPlcIwh[3mlbHWgZZQhTzBxR{GgdIhie2V? NF;OS5MzPjdyN{i4NS=>
Hep3B NWe4coxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUCwMVExKM7:TR?= MkHMOUBl MWDEUXNQ MnG5TWM2OD1yLkC4JO69VQ>? M2nwXFI3PTd3MU[3
HCCLM3 M3HqVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHOfFIxNTFyIN88US=> NVPCSosxPSCm MoXmSG1UVw>? M1TBWmlEPTB;MD6xOEDPxE1? NFH3NoYzPjV5NUG2Oy=>
HuH7 M{HE[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWWwMVExKM7:TR?= NWnkW4EyPSCm NVvHXo06TE2VTx?= Ml7WTWM2OD1yLkKxJO69VQ>? M1HMblI3PTd3MU[3
HepG2 Mnv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLGVYwxNTFyIN88US=> MoXPOUBl NIjnPXVFVVOR NFXWS|lKSzVyPUCuN|Qh|ryP MmTjNlY2PzVzNke=
SMMC7721 M1j5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDmNE0yOCEQvF2= MmG2OUBl NHr5e3VFVVOR MYTJR|UxRTBwNEGg{txO NFjqRY8zPjV5NUG2Oy=>
BEL7402 NFj0cJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvDTHJEOC1zMDFOwG0> NHrxeZA2KGR? M{\ZZWROW09? NWfOZWxjUUN3ME2wMlQ4KM7:TR?= MYSyOlU4PTF4Nx?=
MHCC97H NVH4clE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4r1OlAuOTBizszN NVmzPIQyPSCm NFWybmJFVVOR NWj0WldnUUN3ME2wMlQyKM7:TR?= NUjrNGEzOjZ3N{WxOlc>
Hep3B MX3D[YxtKEO7Y3zlJGF{e2G7 MkDRNE4yNzBwNT:yMlUh|ryP NWjqfY86PDhiaB?= NYHXeph3TE2VTx?= NXvMbJhWdGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZiSFPDJINmdGy|IHnuJJN2[i2JMTDwbIF{\cLi NX7qcXJGOjZ3N{WxOlc>
HCCLM3 M3:wdmNmdGxiQ4njcIUhSXO|YYm= MnLGNE4yNzBwNT:yMlUh|ryP MYS0PEBp NYmwWpE3TE2VTx?= M13XU4xm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKEiFQzDj[YxteyCrbjDzeYIuTzFicHjhd4XDqA>? NGDTc4EzPjV5NUG2Oy=>
Hep3B MlXLRZBweHSxc3nzJGF{e2G7 NGexNJYxNjFxMD61M|IvPSEQvF2= MnXHOFghcA>? NHjifI1FVVOR NEHUeIRi[3SrdnH0[ZMh[2G|cHHz[U0{KGGwZDDjZZNx[XOnLUmg[ZhxemW|c3nvckBidmRiaX7keYNm\CCSQWLQJINt\WG4YXflJIF{KHenbHygZZMh[3m2b3Podo9u\SClIILlcIVie2ViaX70c{B1cGViY4n0c5Bt[XOvIH\yc40hdWm2b3Poc45lemmj NI\kcpMzPjV5NUG2Oy=>
HCCLM3 NFfYfolCeG:ydH;zbZMhSXO|YYm= MkW5NE4yNzBwNT:yMlUh|ryP Mof4OFghcA>? Mn35SG1UVw>? M3f3foFkfGm4YYTld{Bk[XOyYYPlMVMh[W6mIHPhd5Bie2VvOTDlfJBz\XO|aX;uJIFv\CCrbnT1Z4VlKFCDUmCgZ4xm[X[jZ3WgZZMhf2WubDDhd{BkgXSxY3jyc41mKGNicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21iZoLvcUBucXSxY3jvcoRzcWF? NVzzUGlYOjZ3N{WxOlc>
A549 M{jN[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XxWVAvOS1zMDFOwG0> MWi3NkBp NYjPUmhXcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M{HQUlI3PDF3MkK1
H157 MmXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1mwVlAvOS1zMDFOwG0> NF7T[244OiCq MXPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M371blI3PDF3MkK1
H1299 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLINE4yNTFyIN88US=> NFrUPGc4OiCq NV3mS49LcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NHTPcZMzPjRzNUKyOS=>
A549 M3nNZWZ2dmO2aX;uJGF{e2G7 NV3YU4xUOS9{LkWvOUDPxE1? M{H0TlEzKGh? NVnMbGM6yqC5ZXHrcJkh\GWlcnXhd4VlKEKlbD2yJIxmfmWucx?= M1qybFI3PDF3MkK1
H1299 NFT2VmNHfW6ldHnvckBCe3OjeR?= NIjGOYEyNzJwNT:1JO69VQ>? M{XsNlEzKGh? NGrvTlbDqHenYXvsfUBl\WO{ZXHz[YQhSmOuLUKgcIV3\Wy| MmfaNlY1OTV{MkW=
H157 M17h[2Z2dmO2aX;uJGF{e2G7 NXP5b|g1OS9{LkWvOUDPxE1? MYexNkBp MWXk[YNz\WG|ZXSgSHI1KGW6cILld5Nqd25? NFnaVFEzPjRzNUKyOS=>
H1299 MlvlSpVv[3Srb36gRZN{[Xl? MYOxM|IvPS93IN88US=> M165clEzKGh? NYnNOGdq\GWlcnXhd4VlKESUNDDlfJBz\XO|aX;u NYP5RYtFOjZ2MUWyNlU>
C8161 NW\KTJI2S2WubDDWbYFjcWyrdImgRZN{[Xl? MY[wMVIh|ryP NXvQ[pFrPCCm MXXEUXNQ MlPG[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NXm3fo02OjZ|OUeyNlM>
Mel285 MUjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MoXNNE0zKM7:TR?= NW\Yb45WPCCm NVvEO|RHTE2VTx?= MWfk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MlnENlY{QTd{MkO=
Mel290 NIXLS5JE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NYr2W3JbOC1{IN88US=> MXS0JIQ> NIHJTXZFVVOR M4XjW4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NXrvcJpTOjZ|OUeyNlM>
92.1 MnzIR4VtdCCYaXHibYxqfHliQYPzZZk> MlH5NE0zKM7:TR?= NWfGOmQzPCCm MnPrSG1UVw>? M3TidYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MnnmNlY{QTd{MkO=
Omm1.3 NV\CSFZjS2WubDDWbYFjcWyrdImgRZN{[Xl? MWmwMVIh|ryP NUi2ell6PCCm NHO1[lBFVVOR NGiwTpll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MUmyOlM6PzJ{Mx?=
Mel202 Ml3LR4VtdCCYaXHibYxqfHliQYPzZZk> NIXGUVcxNTJizszN NXjUVYYzPCCm M1Lk[2ROW09? NYrhb|h2\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NHnxdnMzPjN7N{KyNy=>
Mel270 MkXXR4VtdCCYaXHibYxqfHliQYPzZZk> NGfvcncxNTJizszN NXW1T2t4PCCm NIHmS3ZFVVOR NYfDU4hT\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NFrzSVQzPjN7N{KyNy=>
Omm1 M4HpR2NmdGxiVnnhZoltcXS7IFHzd4F6 MXewMVIh|ryP M1voXVQh\A>? MWfEUXNQ M2TtbYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MYGyOlM6PzJ{Mx?=
92.1 NE[2dmFCeG:ydH;zbZMhSXO|YYm= MlfjOVAxKG6P NWjYT2NiPDhiaB?= MkGySG1UVw>? Mn31bY5lfWOnczDhdI9xfG:|aYO= MVuyOlM6PzJ{Mx?=
Omm1.3 NYTORllvSXCxcITvd4l{KEG|c3H5 M4XlOlUxOCCwTR?= NXX2XHJQPDhiaB?= NYHzZXl3TE2VTx?= MWDpcoR2[2W|IHHwc5B1d3Orcx?= M1i1blI3Ozl5MkKz
92.1 NYHFXY9TS2WubDDDfYNt\SCDc4PhfS=> MlXZOVAxKG6P MmftNlQwPDhxN{KgbC=> MkewSG1UVw>? MUTpcoR2[2W|IITo[UBk\WyuIHHjZ5VufWyjdHnvckBifCC|dXKtS|HDqA>? MkmzNlY{QTd{MkO=
Omm1.3 M{e1PGNmdGxiQ4njcIUhSXO|YYm= M{DrfFUxOCCwTR?= MYqyOE81QC95MjDo NUmzeWxkTE2VTx?= NUO2WYxEcW6mdXPld{B1cGViY3XscEBi[2O3bYXsZZRqd25iYYSgd5VjNUdzwrC= MWqyOlM6PzJ{Mx?=
A549 M2nOVGZ2dmO2aX;uJGF{e2G7 Mo[xNVAxNzRyMD:xNFAxKG6P M{LrN|I1KGh? Ml3HeZBz\We3bHH0[ZMh[W6mIHHjeIl3[XSnczDTTXJVOQ>? M4\nWVI3OjF{MUm5
MCF-7 MmTESpVv[3Srb36gRZN{[Xl? NHzC[|EyODBxNECwM|ExODBibl2= NW\rb5JWOjRiaB?= MWn1dJJm\3WuYYTld{BidmRiYXP0bZZifGW|IGPJVnQy MoHvNlYzOTJzOUm=
HEK293 M3HqW2Z2dmO2aX;uJGF{e2G7 NFPEWG0yODBxNECwM|ExODBibl2= NV;HU5M3OjRiaB?= MVf1dJJm\3WuYYTld{BidmRiYXP0bZZifGW|IGPJVnQy NVzu[VRyOjZ{MUKxPVk>
858 NWfjSo5VS2WubDDWbYFjcWyrdImgRZN{[Xl? M4HhSFAuOSEQvF2= MnHBOUBl M1nvXmROW09? M3PXboRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NFnkZokzPjJyNkOzNy=>
DDR2L63V NXrhVHl[S2WubDDWbYFjcWyrdImgRZN{[Xl? NYG2XmN1OC1zIN88US=> M2XkUVUh\A>? MWDEUXNQ MnTF[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MnjINlYzODZ|M{O=
BE(2)-C NVXRbFVrS2WubDDWbYFjcWyrdImgRZN{[Xl? MYmxJO69VQ>? M3\RSFEuPCCm M1LZZYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 MlXNNlYxPjd2NkS=
IMR-32 Mlf6R4VtdCCYaXHibYxqfHliQYPzZZk> NUHWV3NSOSEQvF2= MYixMVQh\A>? NIjaOmRl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? MYqyOlA3PzR4NB?=
JF M4i3UGNmdGxiVnnhZoltcXS7IFHzd4F6 M1PEdFEh|ryP M3zJZVEuPCCm NWr3OXVv\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? NF;1VJYzPjB4N{S2OC=>
BE(2)-M17 M3TEbWNmdGxiVnnhZoltcXS7IFHzd4F6 MYixJO69VQ>? MmfuNU01KGR? NH:0T4Fl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? M3;FeFI3ODZ5NE[0
SK-N-SH M33qUGNmdGxiVnnhZoltcXS7IFHzd4F6 M1LB[FEh|ryP NGjkcYgyNTRiZB?= Mnfa[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> M3naXlI3ODZ5NE[0
SK-N-DZ  NIniOldE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MWWxJO69VQ>? NVe3OFc5OS12IHS= NH;hO|Jl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? NVPZdFNyOjZyNke0OlQ>
HMC-1.1  Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv2OU02ODByIH7N NYnrNZRPPDhiaB?= NE\ybWlFVVOR NHniXWZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M1exflI3ODV3M{Cz
HMC-1.2 M4X1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPEV2NUPS13MECwJI5O M2T0VFQ5KGh? MnHvSG1UVw>? MYHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MX[yOlA2PTNyMx?=
ROSA KIT WT  NUG2VJc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7RXIY2NTVyMECgcm0> NGfqTlY1QCCq MVjEUXNQ NETtd|ZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3G0c|I3ODV3M{Cz
ROSA KIT D816V NHvwUY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nubVUuPTByMDDuUS=> MlXMOFghcA>? MlS4SG1UVw>? NGTROHRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M1jvdlI3ODV3M{Cz
HMC-1.1  M3j6cGFxd3C2b4Ppd{BCe3OjeR?= NFHDZngzODBvNUCwNEBvVQ>? MnrFOFghcA>? NUmzS|ZzTE2VTx?= MlOxbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYOyOlA2PTNyMx?=
HMC-1.2 MmLMRZBweHSxc3nzJGF{e2G7 NHnk[5AzODBvNUCwNEBvVQ>? NHPrRWU1QCCq MmrjSG1UVw>? MVzpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MWiyOlA2PTNyMx?=
ROSA KIT WT  NUTvVndXSXCxcITvd4l{KEG|c3H5 NHvuTlAzODBvNUCwNEBvVQ>? M1PNPVQ5KGh? MkDwSG1UVw>? MV;pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NFu3S24zPjB3NUOwNy=>
ROSA KIT D816V MnvYRZBweHSxc3nzJGF{e2G7 MUOyNFAuPTByMDDuUS=> MXq0PEBp MY\EUXNQ Mk\rbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NWTkfnlROjZyNUWzNFM>
494H MkC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HURlczKGh? NWrlW4pOTE2VTx?= MUnJR|UxRTBwMUKyxtExNjByNDFOwG0> MlLpNlU6PDR3Nk[=
493H NXj6SZNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIC4TWg4OiCq NV7HdGpnTE2VTx?= NVH5dYM2UUN3ME2wMlA1P8LzMD6wNFkh|ryP NHnqbnozPTl2NEW2Oi=>
716H MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHO0U4Q4OiCq NGjCTY9FVVOR Mm\KTWM2OD1yLkKxNuKyOC5yM{Sg{txO M4D0clI2QTR2NU[2
148I NEjLSphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnsO|IhcA>? MWTEUXNQ NW\Bd|NxUUN3ME2wMlI5PMLzMD6wN|Uh|ryP MVuyOVk1PDV4Nh?=
98Sc NYrwZ4twT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzmO|IhcA>? NVLHTXFzTE2VTx?= MVnJR|UxRTBwMUG1xtExNjByNDFOwG0> NV[1PFBXOjV7NES1OlY>
89R NWniU3FYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHvOmo4OiCq M4\yd2ROW09? MVzJR|UxRTBwMUK2xtExNjByMzFOwG0> Mlm2NlU6PDR3Nk[=
494L MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTYO|IhcA>? MV\EUXNQ MlLWTWM2OD1yLkOxO:KyOC5yMUKg{txO MV:yOVk1PDV4Nh?=
493L MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7xdpU4OiCq NXfBVWY2TE2VTx?= Mkf5TWM2OD1yLkC1NOKyOC5yMUGg{txO M17mfVI2QTR2NU[2
148L NI\Rc2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVX3UVJkPzJiaB?= MnvYSG1UVw>? MUXJR|UxRTBwMUS2xtExNjBzNzFOwG0> NWO5NlJnOjV7NES1OlY>
98L NEDPS2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:3NkBp M1\4TGROW09? Mo\VTWM2OD1yLkOwPeKyOC5yMkmg{txO NYXpb5BROjV7NES1OlY>
OS17 NH\jTW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWG3NkBp M3XPUmROW09? MUHJR|UxRTBwMEe5xtExNjByMzFOwG0> NEDY[FQzPTl2NEW2Oi=>
OS9 NWXU[mg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7wO|IhcA>? MmrnSG1UVw>? MmXrTWM2OD1yLkSwOuKyOC5yMkig{txO MnjpNlU6PDR3Nk[=
MG63 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\1bpA2PzJiaB?= Mk\pSG1UVw>? M3K5dGlEPTB;MD6xNVTDuTBwMEK1JO69VQ>? M{PHOVI2QTR2NU[2
SAOS2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDJO|IhcA>? NVPVPFhXTE2VTx?= NHniN2lKSzVyPUCuNlE4yrFyLkCwN{DPxE1? MVqyOVk1PDV4Nh?=
U2OS NVfE[ph[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDzXWQ4OiCq MXrEUXNQ MnvJTWM2OD1yLkG5POKyOC5yMEig{txO NGS1T3MzPTl2NEW2Oi=>
SJSA-1 M2C3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF60RoE4OiCq MkD6SG1UVw>? M1Lp[mlEPTB;MD6xNFDDuTBwMEGwJO69VQ>? M1P6NFI2QTR2NU[2
494H NYe4R24xSXCxcITvd4l{KEG|c3H5 MmrxNE4zPS9yLkWvNU4xKM7:TR?= NEHOVZAzPCCq M1\uNmROW09? MVrpcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> NV3rXlRrOjV7NES1OlY>
148I M2rZfmFxd3C2b4Ppd{BCe3OjeR?= MkjXNE4zPS9yLkWvNU4xKM7:TR?= M3nZSFI1KGh? MWjEUXNQ NFqw[29qdmO{ZXHz[ZMhdGW4ZXzzJI9nKGOuZXH2[YQh[2G|cHHz[U0{yqB? MWeyOVk1PDV4Nh?=
OS17 MmOxRZBweHSxc3nzJGF{e2G7 NIWwSHYxNjJ3L{CuOU8yNjBizszN M2nrT|I1KGh? NV76XYMxTE2VTx?= M{\mfYlv[3KnYYPld{Bt\X[nbIOgc4Yh[2ynYY\l[EBk[XOyYYPlMVPDqA>? M{PHUFI2QTR2NU[2
494H MVvBdI9xfG:|aYOgRZN{[Xl? MXix5qCK|ryP NHTiNWE1QCCq MUPEUXNQ NGjpVW1qdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJk> M{fuUFI2QTR2NU[2
148I MmL1RZBweHSxc3nzJGF{e2G7 MYGx5qCK|ryP M2TLVlQ5KGh? NH3rTZZFVVOR MYLpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bIm= M3vDcFI2QTR2NU[2
OS17 NHjG[VFCeG:ydH;zbZMhSXO|YYm= NFK3SG8y6oDLzszN MmDEOFghcA>? M1HJXGROW09? MULpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bIm= MlPGNlU6PDR3Nk[=
MOLM13 MnL3RZBweHSxc3nzJGF{e2G7 M3n5PVI2OCCwTR?= MXq0PEBp MWjEUXNQ MU\pcoR2[2W|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheXWrenHyeIlvcWJ? MX2yOVA2Ozh{NR?=
MV4-11  NVW1[IdSSXCxcITvd4l{KEG|c3H5 MU[yOVAhdk1? NFrRdHQ1QCCq MXLEUXNQ NGnvcXBqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicYXpfoFzfGmwaXK= MUeyOVA2Ozh{NR?=
MOLM13 MYTGeY5kfGmxbjDBd5NigQ>? MkTTNlUxKG6P M1HHOlI1KGh? Mo\WSG1UVw>? NWH2RVNl\W6qYX7j[ZMheXWrenHyeIlvcWJvaX7keYNm\CCvb4LlJJAzOSxiQlnNMEBidmRiY3zlZZZm\CCSQWLQ M3XCV|I2ODV|OEK1
MV4-11  NHy1T2VHfW6ldHnvckBCe3OjeR?= M3;ud|I2OCCwTR?= NEm1TG8zPCCq MYTEUXNQ MVHlcohidmOnczDxeYl7[XK2aX7pZk1qdmS3Y3XkJI1wemVicEKxMEBDUU1uIHHu[EBkdGWjdnXkJHBCWlB? MVeyOVA2Ozh{NR?=
MOLM13 NEPUTotCeG:ydH;zbZMhSXO|YYm= M1nvXlI2OCCwTR?= NVyzdIxvPDhiaB?= MVnEUXNQ NGLFPYtqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicH;uZZRqdmmk M{HYR|I2ODV|OEK1
MV4-11  NVHZW3dtSXCxcITvd4l{KEG|c3H5 Ml3ONlUxKG6P NX\Qc|VEPDhiaB?= NUe1UHh[TE2VTx?= NGH3SW9qdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicH;uZZRqdmmk M1LxUlI2ODV|OEK1
Hela M13OXGNmdGxiVnnhZoltcXS7IFHzd4F6 Ml3uNE02ODBibl2= MXW3NkBp MmTjSG1UVw>? NW\WVYx4\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MUSyOVAxQTJ7NR?=
HBL-1 NUTQTZZMS2WubDDWbYFjcWyrdImgRZN{[Xl? NWTRTmdPOC13MECgcm0> MVK3NkBp NEX2Z3dFVVOR MoTl[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MnP1NlUxODl{OUW=
HLY-1 NITGc5pE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2XyWlAuPTByIH7N NXq2VVJjPzJiaB?= MXzEUXNQ NELN[4dl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MX[yOVAxQTJ7NR?=
OCI-Ly3 NYTPUINDS2WubDDWbYFjcWyrdImgRZN{[Xl? M3L3UVAuPTByIH7N MYS3NkBp MUHEUXNQ M2\kdIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MYGyOVAxQTJ7NR?=
OCI-Ly10 NYixdGZIS2WubDDWbYFjcWyrdImgRZN{[Xl? M1nNVlAuPTByIH7N MnfHO|IhcA>? Mk[1SG1UVw>? M3TWZ4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NXrIT21OOjVyMEmyPVU>
SU-DHL-4 MXvD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmjjNE02ODBibl2= MkHPO|IhcA>? MXTEUXNQ NEfrcXRl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= Mkm5NlUxODl{OUW=
SU-DHL-5 NYK2fmc5S2WubDDWbYFjcWyrdImgRZN{[Xl? MVWwMVUxOCCwTR?= MUm3NkBp NIrkVJVFVVOR Ml71[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M4PVNVI2ODB7Mkm1
SU-DHL-6 MW\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFP0PWQxNTVyMDDuUS=> NFHYV4k4OiCq MY\EUXNQ NW\OXFg5\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MkS0NlUxODl{OUW=
SU-DHL-10 NUnzVoN4S2WubDDWbYFjcWyrdImgRZN{[Xl? MlvHNE02ODBibl2= NIjjRpU4OiCq NUP5PJhDTE2VTx?= NGL3OGhl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= Mn\ENlUxODl{OUW=
RC-K8 NX[0NHZ6S2WubDDWbYFjcWyrdImgRZN{[Xl? MYOwMVUxOCCwTR?= NH;RTYY4OiCq NHjIeWRFVVOR NUm2[XVl\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M4TjR|I2ODB7Mkm1
OCI-Ly8 M{S3N2NmdGxiVnnhZoltcXS7IFHzd4F6 M{fBOlAuPTByIH7N Mn3TO|IhcA>? MUfEUXNQ MWLk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mmm4NlUxODl{OUW=
OCL-Ly18 MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NV3OXVd4OC13MECgcm0> NYrTSJJQPzJiaB?= M2LmNWROW09? Mnmz[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MYmyOVAxQTJ7NR?=
OCI-Ly3 MoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3E[mcyPzJxMkWwM|UxOCCwTR?= NVXiNY1ROi95IHS= NYD6UFZJTE2VTx?= MV3pcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2IHH0JJN2[i2JMTD3bZRpKG2rbnntZYwh[2WubDDk[YF1cMLi NH\5b5ozPTByOUK5OS=>
OCI-Ly8 NVrxV|F1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7tNVczNzJ3MD:1NFAhdk1? MVqyM|ch\A>? M2nP[GROW09? NULCOG95cW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC|dXKtS|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=> MVKyOVAxQTJ7NR?=
SU-DHL-4 MnHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHiNVczNzJ3MD:1NFAhdk1? NIH5[G4zNzdiZB?= M13jRmROW09? NH\nboNqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg M2Hq[lI2ODB7Mkm1
SU-DHL-10 NUS0eIpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTZNVczNzJ3MD:1NFAhdk1? NVPKUnJMOi95IHS= M37NRmROW09? MlvPbY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?= NGOydHIzPTByOUK5OS=>
OCI-Ly3 MkT6RZBweHSxc3nzJGF{e2G7 NIjFVnEyPzJxMkWwJI5O NWrQXWZWP2R? NF;mWnJFVVOR NFrqV2JqdmO{ZXHz[ZMh[2G|cHHz[U0{NzdiYXP0bZZqfHoEoIPp[45q\mmlYX70cJk> NWj5VnBEOjVyMEmyPVU>
OCI-Ly8 M2TzTWFxd3C2b4Ppd{BCe3OjeR?= MWGxO|IwOjVyIH7N NWP0V2tLP2R? M1j2VmROW09? Mm\RbY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 NFXTWIozPTByOUK5OS=>
SU-DHL-4 MXrBdI9xfG:|aYOgRZN{[Xl? MVixO|IwOjVyIH7N MVS3[C=> NG\6R4hFVVOR M1XCbIlv[3KnYYPld{Bk[XOyYYPlMVMwPyCjY4Tpeol1gcLic3nncolncWOjboTsfS=> M1i3XFI2ODB7Mkm1
SU-DHL-10 NIPOdG9CeG:ydH;zbZMhSXO|YYm= MYmxO|IwOjVyIH7N NEf4S484\A>? MV7EUXNQ MojPbY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 NXHz[olPOjVyMEmyPVU>

... Click to View More Cell Line Experimental Data

In vivo (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. [1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. [2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: MC 11060 cells
  • Concentrations: ~500 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Mice bearing NMC 797 xenografts
  • Formulation: 5% DMSO in 5% dextrose
  • Dosages: 50 mg/kg
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL warmed (199.12 mM)
Ethanol 91 mg/mL (199.12 mM)
Water <1 mg/mL
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 456.99
Formula

C23H25ClN4O2S

CAS No. 1268524-70-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy (+)-JQ1 | (+)-JQ1 supplier | purchase (+)-JQ1 | (+)-JQ1 cost | (+)-JQ1 manufacturer | order (+)-JQ1 | (+)-JQ1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID